A PHASE 2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH TALAZOPARIB IN PATIENTS WITH BRCA OR ATM MUTANT TUMORS
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs Avelumab (Primary) ; Talazoparib (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Acronyms Javelin BRCA/ATM
- Sponsors Pfizer
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 28 Jun 2018 New trial record
- 26 Jun 2018 Status changed from not yet recruiting to recruiting.